Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ

Cancer Cell

Volumn 5, Issue 6, 2004, Pages 565-574

  Hedvat, Michael ^a   Jain, Anjali ^a   Carson, Dennis A ^b   Leoni, Lorenzo M ^c   Huang, Ganghua ^a   Holden, Stuart ^a   Lu, Desheng ^b   Corr, Maripat ^b   Fox, William ^a   Agus, David B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Salmedix Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ETODOLAC; HISTAMINE H1 RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PERTUZUMAB; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALIA;

EID: 2942521503     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.05.014     Document Type: Article

References (47)

1. Adachi S., Leoni L.M., Carson D.A., Nakahata T. Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol. 111:2004;107-123
2. Agus D.B., Cordon-Cardo C., Fox W., Drobnjak M., Koff A., Golde D.W., Scher H.I. Prostate cancer cell cycle regulators. response to androgen withdrawal and development of androgen independence J. Natl. Cancer Inst. 91:1999;1869-1876. a
3. Agus D.B., Scher H.I., Higgins B., Fox W.D., Heller G., Fazzari M., Cordon-Cardo C., Golde D.W. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 59:1999;4761-4764. b
4. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2:2002;127-137
5. Allison M.C., Howatson A.G., Torrance C.J., Lee F.D., Russell R.I. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 327:1992;749-754
6. Baek S.J., Wilson L.C., Hsi L.C., Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278:2003;5845-5853
7. Corey E., Quinn J.E., Buhler K.R., Nelson P.S., Macoska J.A., True L.D., Vessella R.L. LuCaP 35. a new model of prostate cancer progression to androgen independence Prostate. 55:2003;239-246
8. Camp H.S., Tafuri S.R. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem. 272:1997;10811-10816
9. Demerson C.A., Humber L.G., Abraham N.A., Schilling G., Martel R.R., Pace-Asciak C. Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J. Med. Chem. 26:1983;1778-1780
10. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., Koeffler H.P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA. 95:1998;8806-8811
11. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272:1997;18779-18789
12. Fajas L., Fruchart J.C., Auwerx J. PPARgamma3 mRNA. a distinct PPARgamma mRNA subtype transcribed from an independent promoter FEBS Lett. 438:1998;55-60
13. Floyd Z.E., Stephens J.M. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J. Biol. Chem. 277:2002;4062-4068
14. Green S. Ppar. a mediator of peroxisome proliferator action Mutat. Res. 333:1995;101-109
15. Green H., Kehinde O. Sublines of mouse 3T3 cells that accumulate lipid. Cell. 1:1974;113-116
16. Han S., Sidell N. Peroxisome-proliferator-activated-receptor gamma (PPARgamma) independent induction of CD36 in THP-1 monocytes by retinoic acid. Immunology. 106:2002;53-59
17. Hauser S., Adelmant G., Sarraf P., Wright H.M., Mueller E., Spiegelman B.M. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 275:2000;18527-18533
18. Hisatake J.I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H.P. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 60:2000;5494-5498
19. Koeffler H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 9:2003;1-9
20. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., Miyoshi I., Koeffler H.P. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:1998;3344-3352
21. Lange C.A., Shen T., Horwitz K.B. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. USA. 97:2000;1032-1037
22. Lavoie J.N., L'Allemain G., Brunet A., Muller R., Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271:1996;20608-20616
23. Lee R.J., Albanese C., Fu M., D'Amico M., Lin B., Watanabe G., Haines G.K. 3rd, Siegel P.M., Hung M.C., Yarden Y., et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20:2000;672-683
24. Lu D., Zhao Y., Tawatao R., Cottam H.B., Sen M., Leoni L.M., Kipps T.J., Corr M., Carson D.A. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 101:2004;3118-3123
25. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., Oh W., Demetri G., Figg W.D., Zhou X.P., et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. USA. 97:2000;10990-10995
26. Na H.K., Surh Y.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem. Pharmacol. 66:2003;1381-1391
27. Nagabhushan M., Miller C.M., Pretlow T.P., Giaconia J.M., Edgehouse N.L., Schwartz S., Kung H.J., de Vere White R.W., Gumerlock P.H., Resnick M.I., et al. CWR22. the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar Cancer Res. 56:1996;3042-3046
28. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res. 63:2003;958-964
29. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., Thomazy V.A., Evans R.M. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4:1998;1058-1061
30. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., Holden S.A., Chen L.B., Singer S., Fletcher C., Spiegelman B.M. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 4:1998;1046-1052
31. Segawa Y., Yoshimura R., Hase T., Nakatani T., Wada S., Kawahito Y., Kishimoto T., Sano H. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate. 51:2002;108-116
32. Shao D., Rangwala S.M., Bailey S.T., Krakow S.L., Reginato M.J., Lazar M.A. Interdomain communication regulating ligand binding by PPAR-gamma. Nature. 396:1998;377-380
33. Shen T., Horwitz K.B., Lange C.A. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell. Biol. 21:2001;6122-6131
34. Sporn M.B., Suh N., Mangelsdorf D.J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med. 7:2001;395-400
35. Takayasu H., Horie H., Hiyama E., Matsunaga T., Hayashi Y., Watanabe Y., Suita S., Kaneko M., Sasaki F., Hashizume K., et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin. Cancer Res. 7:2001;901-908
36. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2. tissue-specific regulator of an adipocyte enhancer Genes Dev. 8:1994;1224-1234. a
37. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1994;1147-1156. b
38. Tontonoz P., Singer S., Forman B.M., Sarraf P., Fletcher J.A., Fletcher C.D., Brun R.P., Mueller E., Altiok S., Oppenheim H., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA. 94:1997;237-241
39. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252
40. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gel to nitrocellulose sheets. procedure and some applications Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354
41. Wainstein M.A., He F., Robinson D., Kung H.J., Schwartz S., Giaconia J.M., Edgehouse N.L., Pretlow T.P., Bodner D.R., Kursh E.D., et al. CWR22. androgen-dependent xenograft model derived from a primary human prostatic carcinoma Cancer Res. 54:1994;6049-6052
42. Wang C., Fu M., Amico M., Albanese C., Zhou J., Brownlee M., Lisanti P., Chatterjee K., Lazar M., Pestell R. Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-acivated receptor γ-dependent repression of cyclin D1. Mol. Cell Biol. 21:2001;3057-3070
43. Wang C., Pattabiraman N., Zhou J.N., Fu M., Sakamaki T., Albanese C., Li Z., Wu K., Hulit J., Neumeister P., et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol. Cell. Biol. 23:2003;6159-6173
44. Watanabe G., Albanese C., Lee R.J., Reutens A., Vairo G., Henglein B., Pestell R.G. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol. Cell. Biol. 18:1998;3212-3222
45. Yang Z., Bagheri-Yarmand R., Balasenthil S., Hortobagyi G., Sahin A.A., Barnes C.J., Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin. Cancer Res. 9:2003;3198-3203
46. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2001;127-137
47. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Rao M.S., Reddy J.K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene. alternative promoter use and different splicing yield two mPPAR gamma isoforms Proc. Natl. Acad. Sci. USA. 92:1995;7921-7925